Sagimet Biosciences Announces Completion Of Enrollment Of 120 Patients For Phase 3 Clinical Trial By Its Partner Ascletis Of Denifanstat Combined With Bevacizumab For Treatment Of Recurrent Glioblastoma
Portfolio Pulse from Benzinga Newsdesk
Sagimet Biosciences Inc. (NASDAQ:SGMT) announced that its partner, Ascletis Bioscience Co. Ltd., has completed enrollment of 120 patients for a Phase 3 clinical trial of denifanstat combined with bevacizumab for treatment of recurrent glioblastoma. Sagimet licensed the rights to develop and commercialize denifanstat in China, Hong Kong, Macau, and Taiwan to Ascletis in 2019. Sagimet's FASCINATE-2 Phase 2b clinical trial for denifanstat in nonalcoholic steatohepatitis patients is fully enrolled and results are expected in Q1 2024.
September 27, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sagimet Biosciences' partner Ascletis has completed enrollment for a Phase 3 trial of denifanstat for recurrent glioblastoma. Sagimet's own Phase 2b trial for denifanstat in NASH patients is fully enrolled, with results due in Q1 2024.
The completion of patient enrollment for the Phase 3 trial of denifanstat is a significant milestone for Sagimet Biosciences. This could potentially lead to positive results, which would be beneficial for the company's stock. Additionally, the full enrollment for Sagimet's own Phase 2b trial for denifanstat in NASH patients indicates progress in the company's pipeline, which could also positively impact the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100